Matthew T. Breneman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Matthew T. Breneman has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Aaron M. LeBeau
Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA
25 shared publications - Abigail E. Jackson
Department of Biochemistry, University of Utah, Salt Lake City, UT, USA
25 shared publications - David Kosoff
Department of Medicine University of Wisconsin‐Madison Madison Wisconsin USA
25 shared publications - Emma E. Recchia
University of Wisconsin–Madison 1 Madison, WI
25 shared publications - Erika Heninger
University of Wisconsin–Madison 1 Madison, WI
25 shared publications - Gihan S. Gunaratne
Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA
25 shared publications
Latest Publications
- Open Access
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 2 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
PET/CT imaging of FAP in vivo. A, Representative PET/CT images of mice bearing subcutaneous 22Rv1/hPrCSC-44 xenografts (white arrowhead). Mice (n = 3/group) received 3.5 MBq (25–50 µg, 7.7 µg/MBq) of [89Zr]Zr-HuB12, 3.6 MBq (25–50 µg, 7.5 µg/MBq) [89Zr]Zr-F19 or 3.4 MBq (25–50 µg, 7.9 µg/MBq) [89Zr]Zr-J591 via tail vein and were imaged at the indicated timepoints. B, Quantitative analysis of subcutaneous xenografts from mice (n = 3/group) revealed significantly higher [89Zr] uptake in the tumors of [89Zr]Zr-HuB12 administered animals compared with the [89Zr]Zr-F19 or [89Zr]Zr-J591 at all timepoints postinjection. Values represent mean ± SEM. *, P ≤ 0.05; **, P ≤ 0.01; ****, P ≤ 0.0001. C, Radio-competition cell binding results using [89Zr]Zr-HuB12 and either the FAP-positive hPrCSC-44 or FAP-negative 22Rv1 cell line. The IC50 was only determinable for hPrCSC-44 and was measured at 11.6 nmol/L.
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 2 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
PET/CT imaging of FAP in vivo. A, Representative PET/CT images of mice bearing subcutaneous 22Rv1/hPrCSC-44 xenografts (white arrowhead). Mice (n = 3/group) received 3.5 MBq (25–50 µg, 7.7 µg/MBq) of [89Zr]Zr-HuB12, 3.6 MBq (25–50 µg, 7.5 µg/MBq) [89Zr]Zr-F19 or 3.4 MBq (25–50 µg, 7.9 µg/MBq) [89Zr]Zr-J591 via tail vein and were imaged at the indicated timepoints. B, Quantitative analysis of subcutaneous xenografts from mice (n = 3/group) revealed significantly higher [89Zr] uptake in the tumors of [89Zr]Zr-HuB12 administered animals compared with the [89Zr]Zr-F19 or [89Zr]Zr-J591 at all timepoints postinjection. Values represent mean ± SEM. *, P ≤ 0.05; **, P ≤ 0.01; ****, P ≤ 0.0001. C, Radio-competition cell binding results using [89Zr]Zr-HuB12 and either the FAP-positive hPrCSC-44 or FAP-negative 22Rv1 cell line. The IC50 was only determinable for hPrCSC-44 and was measured at 11.6 nmol/L.
- Open Access
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Proliferation and survival marker gene expression
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Proliferation and survival marker gene expression
- Open Access
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Determining the therapeutic window in the Stacks
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Determining the therapeutic window in the Stacks
- Open Access
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
ADC efficacy in multiple cell lines
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
ADC efficacy in multiple cell lines
- Open Access
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Determining the therapeutic window in the Stacks
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Determining the therapeutic window in the Stacks
- Open Access
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
ADC efficacy in multiple cell lines
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
ADC efficacy in multiple cell lines
- Open Access
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 4 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Specificity of huB12-MMAE treatment in the Stacks. A, Workflow of treatment and analysis of CAF-tumor models using huB12-MMAE. B, Viability analysis of CAFS (hPrCSC-44/top) and tumor cells (22Rv1/bottom) in monoculture (left) and coculture (right) using indicated concentrations of huB12-MMAE for 72 hours.
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 4 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Specificity of huB12-MMAE treatment in the Stacks. A, Workflow of treatment and analysis of CAF-tumor models using huB12-MMAE. B, Viability analysis of CAFS (hPrCSC-44/top) and tumor cells (22Rv1/bottom) in monoculture (left) and coculture (right) using indicated concentrations of huB12-MMAE for 72 hours.